At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
PF-04447943 +1 moredrug
Likely dose
PF-04447943 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR OPEN, RANDOMIZED, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-04447943 IN MILD TO MODERATE ALZHEIMER'S DISEASE SUBJECTS ON STABLE DONEPEZIL THERAPY
In Brief
A Phase 1 clinical trial evaluating PF-04447943 and Placebo for Alzheimer's Disease. Completed, enrolled 15 participants across 3 sites.
Detailed Summary
The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and distribution of both PF-04447943 and donepezil.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartOct 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedOct 2, 2009
Enrollment StartOct 26, 2009
Primary CompletionJul 5, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.8 years ago
Interventions
PF-04447943drug
25 mg of PF-04447943 orally every 12 hours for 7 days
Placebodrug
25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days